Noninvasix will be the first company to non-invasively monitor the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time.
Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements and evidence will expand the use and clinical impact of our technology into other indications and settings.
Noninvasix is backed by 15 years of optoacoustic research and more than $6.5 million in research grants.
Company’s Keywords:
medical devices, ventures for good, diagnostics, medical, health care, optoacoustics, patient monitoring, oximetry
<4
<3000000
<2007
Your request has been submitted successfully.
Own or work here?